Radioisotope Products and the Medicine of the Future: an IAEA Perspective

The production and application of radioisotopes and radiopharmaceuticals is a major peaceful application of nuclear science and technology and has opened new gateways for nuclear medicine in critical human diseases. Advances in the production of radioisotopes via nuclear reactors, accelerators, fission, etc. has facilitated the access to these products for Member States. ⁹⁹Mo, ¹³¹I, ¹⁷⁷Lu are among the most essential radioisotopes for nuclear medicine and human health and their production and availability always has been an important theme for professional societies and the International Atomic Energy Agency (IAEA). In the meantime, a large list of theranostic radioisotopes including but not limited to ⁸⁹Zr, ⁶⁸Ga, ²²⁵Ac, Cu-series, Sc-series, Tb-series etc. has provided a powerful toolbox for clinicians and the IAEA is taking steps to ensure their safe and appropriate application in radiopharmacy. The Agency promotes the production and application routes, including research reactors, cyclotrons, linear accelerators, and other cutting-edge methods, according to international and national guidelines and regulations. The IAEA also conducts activities such as Coordinated Research Projects (CRPs), Technical Meetings (TMs), national/regional training courses and conferences, to support and join forces with international professional societies in the development of human resources and research and development activities. Development of databases and freely available publications for all Member States are other useful means to support Member States in radiopharmaceutical sciences.

1. Radchenko V, Morgenstern A, Jalilian AR, Ramogida CF, Cutler C, Duchemin C, et al. Production and supply of α-particle-emitting radionuclides for targeted α-therapy. J Nucl Med. 2021;62(11):1495–503. https://doi.org/10.2967/jnumed.120.261016

2. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193–9. https://doi.org/10.7150/ijms.3635

3. Jalilian AR, Osso JA. Production, applications and status of zirconium-89 immunoPET agents. J Radioanal Nucl Chem. 2017;314:7–21. https://doi.org/10.1007/s10967-017-5358-z

4. Jalilian AR, Gizawy MA, Alliot C, Takacs S, Chakarborty S, Rovais MRA, et al. IAEA activities on 67Cu, 186Re, 47 Sc theranostic radionuclides and radiopharmaceuticals. Curr Radiopharm. 2021;14(4):306–14. https://doi.org/10.2174/1874471013999200928162322

5. Jalilian AR, Osso Jr JA, Vera-Araujo J, Kumar V, Harris MJ, Gutfilen B, et al. IAEA contribution to the development of 64Cu radiopharmaceuticals for theranostic applications. Q J Nucl Med Mol Imaging. 2020;64(4):338–45. https://doi.org/10.23736/s1824-4785.20.03302-6